GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xlife Sciences AG (XSWX:XLS) » Definitions » Debt-to-Revenue

Xlife Sciences AG (XSWX:XLS) Debt-to-Revenue : 44.16 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Xlife Sciences AG Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Xlife Sciences AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF0.95 Mil. Xlife Sciences AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF55.57 Mil. Xlife Sciences AG's annualized Revenue for the quarter that ended in Dec. 2023 was CHF1.28 Mil. Xlife Sciences AG's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 44.16.


Xlife Sciences AG Debt-to-Revenue Historical Data

The historical data trend for Xlife Sciences AG's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xlife Sciences AG Debt-to-Revenue Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial 108.74 131.53 78.13 58.70 57.21

Xlife Sciences AG Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.13 81.07 46.00 79.81 44.16

Competitive Comparison of Xlife Sciences AG's Debt-to-Revenue

For the Biotechnology subindustry, Xlife Sciences AG's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xlife Sciences AG's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's Debt-to-Revenue falls into.



Xlife Sciences AG Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Xlife Sciences AG's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.951 + 55.573) / 0.988
=57.21

Xlife Sciences AG's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.951 + 55.573) / 1.28
=44.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Xlife Sciences AG Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Xlife Sciences AG's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Xlife Sciences AG (XSWX:XLS) Business Description

Traded in Other Exchanges
Address
Talacker 35, Zürich, CHE, 8001
Xlife Sciences AG is a Swiss company with a focus on performance technologies in life sciences. The company allows its investors a very early and direct Entry into the further development of innovative and future-oriented technologies.

Xlife Sciences AG (XSWX:XLS) Headlines

No Headlines